^
Association details:
| Biomarker: | LMNA-NTRK1 G667C |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | FCN-098 (Trk inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FCN-098, a novel second-generation TRK inhibitor, overcomes TRK resistance mutations in vitro and in vivo
Published date:
05/15/2020
Excerpt:
Consistent with in vitro results, FCN-098 showed remarkable anti-tumor activity in xenograft models driven by WT or mutant TRK fusions in a dose-dependent manner. In particular, the anti-tumor activity of FCN-098 was superior to another second-generation TRK inhibitor LOXO-195 at the same dose in xenografts driven by TPM3-TRKA G595R or ETV6-TRKC G623R mutation, and exhibited comparable potency to LOXO-195 in LMNA-TRKA G667C-driven xenografts.
